Moderna: Speed Of COVID-19 Vaccine Now Hinges On Enrolling The Right Patients

 
• By Sarah Karlin-Smith

Recruiting the right patient population for Phase III trials of COVID-19 vaccines will be a key factor in how fast any candidate can come to market. The challenge, which will likely mean enrolling patients who often are underrepresented in trials, is keeping Moderna's Chief Medical Officer up at night. The company also talked vaccine distribution, what it feels it owes the US government for its financial support, and pricing of its potential mRNA vaccine on a recent New York Academy of Sciences webinar.

Conceptual hand writing showing Enroll. Business photo text officially register as member of institution or student on course
Moderna is proactively working to ensure it recruits a diverse patient base that will hit clinical outcomes for its Phase III vaccine trial • Source: Shutterstock

More from Vaccines

More from Pink Sheet